|
Merck sees higher 2008 earnings as new drugs shine
2007-12-04
Merck & Co (MRK.N) on Tuesday forecast earnings would rise in 2008 as sales of new medicines offset the loss of exclusive U.S. rights to its Fosamax osteoporosis drug. Merck projected 2008 earnings, excluding special items, of $3.28 to $3.38 per share. The company anticipates 2007 earnings of $3.08 to $3.14 per share excluding special items. Merck projected 2008 net earnings of $3.96 to $4.06 per share, including a big gain associated with its partnership with AstraZeneca Plc (AZN.L). (Reporting by Lewis Krauskopf; editing by John Wallace)
|  | | | Profile |
News105 | Gallery | Links | |
 | |
|
|
|